Related Experiment Videos
Pulmonary infection due to methicillin-resistant Staphylococcus aureus
M T Cafferkey1, E Abrahamson, A Bloom
1Department of Medicine, Royal City of Dublin Hospital, Ireland.
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) are now causing severe clinical infection on a worldwide basis. Pulmonary infection due to MRSA although widely reported is poorly documented. We report the predisposing factors, underlying diseases, treatment and outcome in 4 patients with pneumonia, 3 patients with empyema thoracis, 1 patient with pneumonia and empyema thoracis, 1 patient with pneumonia plus lobectomy wound infection and 2 patients with lung abscess. Vancomycin was highly effective in treatment, a finding compatible with experience treating other severe MRSA infections.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) causes severe lung infections like pneumonia and empyema. Vancomycin proved highly effective in treating these challenging MRSA pulmonary cases.
Area of Science:
- Infectious Diseases
- Pulmonary Medicine
- Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a global cause of severe infections.
- Pulmonary infections from MRSA are clinically significant but under-documented.
Purpose of the Study:
- To document predisposing factors, diseases, treatments, and outcomes of MRSA pulmonary infections.
- To evaluate the efficacy of Vancomycin in treating these infections.
Main Methods:
- Case series reporting on 11 patients with various MRSA pulmonary conditions.
- Analysis of patient data including underlying diseases and treatment responses.
Main Results:
- Reported cases included pneumonia, empyema thoracis, lung abscess, and surgical site infections.
- Vancomycin demonstrated high effectiveness in treating the documented MRSA pulmonary infections.
Conclusions:
- MRSA poses a significant threat in pulmonary infections.
- Vancomycin is an effective treatment option for severe MRSA pulmonary disease.